CD32b Antibody Modulation for Viral Infection Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments for viral infections, particularly those caused by Coronaviridae such as SARS-COV-2, often result in severe acute respiratory distress syndrome due to the lack of effective interferon response and neutrophil activation, leading to significant health threats and high mortality rates.
Innovation Solution
Administration of a therapeutically effective amount of a CD32b antagonist or agonist, specifically a humanized monoclonal antibody or antigen-binding fragment, to modulate immune cell function and restore interferon production and neutrophil activity, thereby mitigating the severity of viral infections and associated respiratory distress.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing treatments for viral infections are administered, then viral infection is addressed, but severe acute respiratory distress syndrome develops due to lack of effective interferon response and neutrophil activation
Solution Approach 1:
The patent introduces CD32b antagonists or agonists as intermediary substances that mediate between the viral infection and the immune system. These compounds specifically target CD32b receptors on immune cells to restore interferon production and neutrophil activation, thereby preventing severe acute respiratory distress syndrome while treating the viral infection.
Solution Approach 2:
The patent changes the immunological parameters of the subject by administering CD32b modulators that alter interferon-alpha secretion levels and neutrophil population dynamics. This parameter modification restores the immune response to effective levels, resolving the contradiction between treating infection and avoiding respiratory distress.
2Reliability
If interferon response is not activated, then viral infection progresses, but severe respiratory distress occurs without proper immune modulation
Solution Approach 1:
CD32b modulators serve as intermediaries that specifically target the immune response pathway. By binding to CD32b receptors, these compounds precisely regulate interferon production and neutrophil activation, ensuring effective viral clearance while preventing the harmful overresponse that leads to respiratory distress.
3Reliability
If neutrophil activation is insufficient, then viral clearance is impaired, but excessive or uncontrolled immune response causes respiratory distress
Solution Approach 1:
The CD32b modulator acts as a controlled intermediary that regulates neutrophil activation through specific receptor binding. This mediation ensures sufficient neutrophil response for effective viral clearance while preventing uncontrolled immune activation that would cause respiratory distress, achieving a balanced therapeutic effect.
Data Source
AI summary
The application discloses methods of treating and/or preventing acute respiratory disorder in a subject in need thereof. The application also discloses a method of treating a viral infection, such as Coronaviridae infection by administering to a subject infected with a virus from Coronaviridae with an agonist or antagonist of CD32. Antibodies and antibody binding fragments thereof are disclosed as treatments, and, in some embodiments, the antibody treatment is an antibody against an epitope in CD32b.